Ms. De Backer will serve as Bayer’s head of business development and licensing for its pharmaceuticals division.
She joins from rival J&J, where she led business development efforts in various regions.
“Her breadth of experience in successfully forming and managing external alliances will be one of the key drivers for Bayer’s continued growth, ultimately aimed at providing new medicines and solutions to patients,” Bayer’s pharma division chief Stefan Oelrich, told Endpoints News.
More articles on pharmacy:
FDA approves AbbVie’s $59K rheumatoid arthritis drug
Teva launches generic version of EpiPen for kids
American Regent boosted price of essential hospital product by 1,300%
